RA Capital Management 13F holdings, Q4 2022
Holdings as of December 31, 2022 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 70 US equity positions worth $4.9bn in its Q4 2022 13F filing. The largest position was ASND at 17.2% of the reported book, followed by PCVX and AEROVATE THERAPEUTICS INC. Against the Q3 2022 filing, it opened 8 new positions, added to 16 and reduced 4 among the top 50 holdings.
What did RA Capital Management own in Q4 2022? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2022 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | Healthcare | 17.2% | $849.7m | 6,957,179 | -8% | reduced |
| 2 | PCVX VAXCYTE INC | Healthcare | 5.7% | $280.9m | 5,857,459 | 28% | added |
| 3 | AEROVATE THERAPEUTICS INC | 4.9% | $242.1m | 8,263,982 | 0% | held | |
| 4 | DICE THERAPEUTICS INC | 4.3% | $213.7m | 6,848,911 | 31% | added | |
| 5 | VRNA VERONA PHARMA PLC | 3.3% | $165.1m | 6,317,990 | 4% | added | |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 3.3% | $160.6m | 5,516,067 | 1% | added |
| 7 | DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 3.1% | $151.5m | 7,040,622 | 0% | held | |
| 8 | VOR VOR BIOPHARMA INC | 3.1% | $151.3m | 22,748,880 | 105% | added | |
| 9 | BIIB BIOGEN INC | Healthcare | 3.0% | $147.6m | 532,892 | -43% | reduced |
| 10 | CTKB CYTEK BIOSCIENCES INC | Healthcare | 2.8% | $136.6m | 13,381,054 | 0% | held |
| 11 | LEGN LEGEND BIOTECH CORP | Healthcare | 2.5% | $121.6m | 2,436,223 | 4% | added |
| 12 | AVIDITY BIOSCIENCES INC | 2.5% | $121.0m | 5,454,533 | 152% | added | |
| 13 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 2.4% | $120.4m | 17,202,009 | 0% | held |
| 14 | JANX JANUX THERAPEUTICS INC | Healthcare | 2.3% | $114.2m | 8,670,644 | 0% | held |
| 15 | 89BIO INC | 2.3% | $114.0m | 8,955,410 | 15% | added | |
| 16 | PEPG PEPGEN INC | Healthcare | 2.2% | $108.7m | 8,131,952 | 0% | held |
| 17 | IMMUNOGEN INC | 2.2% | $108.4m | 21,853,958 | 1% | added | |
| 18 | BELLUS HEALTH INC NEW | 2.1% | $102.4m | 12,452,574 | 9% | added | |
| 19 | INHIBRX INC | 1.9% | $95.0m | 3,853,867 | – | new | |
| 20 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.9% | $92.5m | 2,075,000 | 0% | held |
| 21 | ITEOS THERAPEUTICS INC | 1.7% | $86.3m | 4,417,259 | 0% | held | |
| 22 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.7% | $83.8m | 3,984,681 | -19% | reduced |
| 23 | COGT COGENT COMMUNICATIONS HLDGS | Healthcare | 1.4% | $69.4m | 5,999,481 | 49% | added |
| 24 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 1.4% | $69.3m | 4,398,453 | 0% | held |
| 25 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.4% | $69.2m | 9,505,925 | 36% | added |
| 26 | ACRV ACRIVON THERAPEUTICS INC | 1.1% | $55.4m | 4,810,508 | – | new | |
| 27 | TYRA TYRA BIOSCIENCES INC | Healthcare | 1.1% | $55.0m | 7,236,454 | 0% | held |
| 28 | ABOS ACUMEN PHARMACEUTICALS INC | 1.1% | $52.8m | 9,770,773 | 0% | held | |
| 29 | AKERO THERAPEUTICS INC | 1.1% | $52.6m | 958,980 | 0% | held | |
| 30 | CLYM ELIEM THERAPEUTICS INC | 1.0% | $48.3m | 13,150,849 | 0% | held | |
| 31 | GHRS GH RESEARCH PLC | 1.0% | $47.6m | 4,898,373 | 0% | held | |
| 32 | ICOSAVAX INC | 1.0% | $47.4m | 5,963,565 | 0% | held | |
| 33 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 1.0% | $47.1m | 2,407,149 | 14% | added |
| 34 | NKTX NKARTA INC | Healthcare | 0.9% | $46.8m | 7,805,129 | 0% | held |
| 35 | NEWAMSTERDAM PHARMA COMPANY | 0.9% | $43.6m | 4,000,000 | – | new | |
| 36 | RXST RXSIGHT INC | Healthcare | 0.8% | $38.7m | 3,052,796 | 0% | held |
| 37 | ANTX AN2 THERAPEUTICS INC | 0.7% | $36.0m | 3,773,517 | 0% | held | |
| 38 | ALPINE IMMUNE SCIENCES INC | 0.7% | $32.3m | 4,397,368 | 1% | added | |
| 39 | GERN GERON CORP | Healthcare | 0.6% | $31.3m | 12,930,711 | -57% | reduced |
| 40 | DSGN DESIGN THERAPEUTICS INC | Healthcare | 0.6% | $30.5m | 2,971,231 | 7% | added |
| 41 | HILLEVAX INC | 0.6% | $29.4m | 1,760,019 | 0% | held | |
| 42 | KINNATE BIOPHARMA INC | 0.5% | $26.0m | 4,264,144 | 0% | held | |
| 43 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.5% | $25.7m | 880,000 | 0% | held |
| 44 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.5% | $25.7m | 3,009,678 | – | new |
| 45 | CELC CELCUITY INC | Healthcare | 0.4% | $19.6m | 1,400,001 | – | new |
| 46 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.4% | $18.4m | 3,426,286 | – | new |
| 47 | DA32 LIFE SCNCE | 0.3% | $15.0m | 1,500,000 | 0% | held | |
| 48 | SCPHARMACEUTICALS INC | 0.3% | $13.3m | 1,856,904 | – | new | |
| 49 | IMARA INC | 0.3% | $13.3m | 3,250,724 | – | new | |
| 50 | TNYA TENAYA THERAPEUTICS INC | 0.2% | $12.2m | 6,067,483 | 279% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.